Protocol Design White Papers & Case Studies

31. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

32. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

    Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

33. How Expert Medical Information Support Strengthened A Rare Respiratory Therapy Launch 5/26/2026

    Embedded medical information expertise enabled compliant, real‑time scientific engagement with healthcare professionals at a high‑profile congress during a critical product launch.

34. Inspection Facilitation Without Local MAH Presence 5/26/2026

    Local expertise and centralized oversight ensured compliant, well‑coordinated inspections across countries, reducing operational risk and client burden while maintaining consistent authority engagement.

35. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

    In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

36. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

37. Data-Driven Paths To Rare/Ultra-Rare Disease Therapy Approval 5/22/2026

    Explore how integrated regulatory, statistical, and operational expertise can be applied to help sponsors navigate complex development pathways and accelerate global approvals.

38. Reduce Avoidable Protocol Amendments By Anticipating Operational Pitfalls 5/13/2026

    This report examines how amendment drivers vary across therapeutic areas and how those changes impact execution, patient burden, site workload, timelines, and study costs.

39. 5 Questions To Ask Before Selecting A Randomization Partner 5/12/2026

    Choose the right IRT partner for complex master protocols. Learn how adaptive randomisation expertise and flexible technology reduce disruption and keep trials execution-ready.

40. Reducing Inventory Errors In Clinical Trials 5/8/2026

    Can a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.